Literature DB >> 23725603

Colorectal cancer immunotherapy.

Bo Xiang1, Adam E Snook, Michael S Magee, Scott A Waldman.   

Abstract

Antitumor immunotherapy for colorectal cancer has been studied at the bench and bedside for decades. Some clinical trials of cancer immunotherapy have demonstrated a potential benefit for patients with colorectal cancer, yet immunotherapy remains only an experimental option for this disease. Here, we review the major immunotherapeutic approaches currently under investigation for colorectal cancer, including cancer vaccines and adoptive cell therapy. Weakness and advantages of each strategy and progress in clinical trials will be described. Examination of previous and ongoing research in colorectal cancer therapy should define a path towards identification, approval, and mainstream adoption of colorectal cancer immunotherapeutics.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23725603      PMCID： PMC4042089     

Source DB:  PubMed          Journal:  Discov Med        ISSN： 1539-6509            Impact factor:   2.970


  70 in total

Review 1.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.

Authors:  S Hammarström
Journal:  Semin Cancer Biol       Date:  1999-04       Impact factor: 15.707

2.  Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise.

Authors:  M G Hanna; H C Hoover; J B Vermorken; J E Harris; H M Pinedo
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

Review 3.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

Authors:  Giorgio Parmiani; Chiara Castelli; Piero Dalerba; Roberta Mortarini; Licia Rivoltini; Francesco M Marincola; Andrea Anichini
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

4.  Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells.

Authors:  Michael S Turner; Patrice A Cohen; Olivera J Finn
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

5.  Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.

Authors:  Robert M Conry; David T Curiel; Theresa V Strong; Susan E Moore; Karen O Allen; Daunte L Barlow; Denise R Shaw; Albert F LoBuglio
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

6.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

7.  Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.

Authors:  Scott A Waldman; Terry Hyslop; Stephanie Schulz; Alan Barkun; Karl Nielsen; Janis Haaf; Christine Bonaccorso; Yanyan Li; David S Weinberg
Journal:  JAMA       Date:  2009-02-18       Impact factor: 56.272

8.  Heterogeneity of mucin gene expression in normal and neoplastic tissues.

Authors:  S B Ho; G A Niehans; C Lyftogt; P S Yan; D L Cherwitz; E T Gum; R Dahiya; Y S Kim
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

9.  Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

Authors:  F Berard; P Blanco; J Davoust; E M Neidhart-Berard; M Nouri-Shirazi; N Taquet; D Rimoldi; J C Cerottini; J Banchereau; A K Palucka
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

10.  MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy.

Authors:  Sara K Lindén; Yong H Sheng; Alison L Every; Kim M Miles; Emma C Skoog; Timothy H J Florin; Philip Sutton; Michael A McGuckin
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823
View more
  27 in total

Review 1.  Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.

Authors:  Srikanth Santhanam; David M Alvarado; Matthew A Ciorba
Journal:  Transl Res       Date:  2015-08-03       Impact factor: 7.012

Review 2.  Basics to advances in nanotherapy of colorectal cancer.

Authors:  Ankita Tiwari; Shivani Saraf; Ankit Jain; Pritish K Panda; Amit Verma; Sanjay K Jain
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

3.  Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy.

Authors:  Kazumi Okamura; Satoshi Nagayama; Tomohiro Tate; Hiu Ting Chan; Kazuma Kiyotani; Yusuke Nakamura
Journal:  J Transl Med       Date:  2022-05-23       Impact factor: 8.440

4.  LncRNA NEAT1 Promotes the Malignant Progression of Colorectal Cancer by Targeting ZEB1 via miR-448.

Authors:  Hanquan Wu; Dengwen Dong; Jiwei Wang; Shiwen Yin; Yuanxiang Gong; Chao Yang; Yihan Bai; Junyi Wang; Yanhong Du
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 5.  The emerging role of immunotherapy in colorectal cancer.

Authors:  David Lynch; Adrian Murphy
Journal:  Ann Transl Med       Date:  2016-08

Review 6.  MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.

Authors:  Xiang Li; Jing Nie; Qian Mei; Wei-Dong Han
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

Review 7.  Therapeutic vaccines for cancer: an overview of clinical trials.

Authors:  Ignacio Melero; Gustav Gaudernack; Winald Gerritsen; Christoph Huber; Giorgio Parmiani; Suzy Scholl; Nicholas Thatcher; John Wagstaff; Christoph Zielinski; Ian Faulkner; Håkan Mellstedt
Journal:  Nat Rev Clin Oncol       Date:  2014-07-08       Impact factor: 66.675

8.  Non-invasive assessment of the efficacy of new therapeutics for intestinal pathologies using serial endoscopic imaging of live mice.

Authors:  Matthias Ernst; Adele Preaudet; Tracy Putoczki
Journal:  J Vis Exp       Date:  2015-03-10       Impact factor: 1.355

9.  Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer.

Authors:  Yun-Huan Zhen; Xiao-Hui Liu; Yuan Yang; Bo Li; Jing-Ling Tang; Qiang-Xing Zeng; Jie Hu; Xing-Nan Zeng; Lu Zhang; Ze-Jun Wang; Xiao-Yun Li; Hui-Xin Ge; Ola Winqvist; Ping-Sheng Hu; Jin Xiu
Journal:  Cancer Immunol Immunother       Date:  2015-05-20       Impact factor: 6.968

10.  Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy.

Authors:  Hui Zhu; Xuejing Yang; Jiali Li; Yanjie Ren; Tianyu Zhang; Chunze Zhang; Jintai Zhang; Jing Li; Yan Pang
Journal:  Biomed Res Int       Date:  2014-07-17       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.